Reports preliminary FY25 revenue $520M, consensus $507.91M. “2025 was an excellent year for Mirum, reflecting the strength and scalability of our purpose-built rare disease operating model,” said Chris Peetz, CEO of Mirum. “We delivered strong global commercial growth, advanced multiple late-stage clinical programs and are expanding our pipeline with the proposed acquisition of Bluejay Therapeutics and brelovitug for HDV. With a strong financial foundation, deep commitment to patients and multiple upcoming clinical catalysts, we enter 2026 well positioned to drive continued execution and value creation.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Announces Strong 2025 Sales and 2026 Outlook
- Mirum Files Patent Suits to Block Livmarli Generics
- Mirum Pharmaceuticals Raises Capital via Private Placement
- Mirum Pharmaceuticals price target raised to $140 from $95 at Citizens
- Mirum Pharmaceuticals price target raised to $100 from $90 at Leerink